Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval in Mainland China for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology's licensing partner CANbridge Pharmaceuticals has received regulatory approval to market NERLYNX (neratinib) in Mainland China.
